A phase I study of chemoembolization with cisplatin and lipiodol for primary and metastatic liver cancer
Twenty patients with either unresectable primary hepatocellular carcinoma or hepatic metastases were entered into a chemoembolization program with cisplatin and lipiodol; 19 patients were evaluable for response. Doses of cisplatin ranged from 40 to 100 mg/m2. Toxicity was tolerable and reversible an...
Gespeichert in:
| Veröffentlicht in: | American journal of clinical oncology 1994-10, Vol.17 (5), p.405-410 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 410 |
|---|---|
| container_issue | 5 |
| container_start_page | 405 |
| container_title | American journal of clinical oncology |
| container_volume | 17 |
| creator | FEUN, L. G REDDY, K. R LIVINGSTONE, A. S ARDALAN, B BENEDETTO, P YRIZARRY, J. M SAVARAJ, N GUERRA, J. J PURSER, R. K WALDMAN, S LEVI, J. U MOFFATT, F MORRELL, L |
| description | Twenty patients with either unresectable primary hepatocellular carcinoma or hepatic metastases were entered into a chemoembolization program with cisplatin and lipiodol; 19 patients were evaluable for response. Doses of cisplatin ranged from 40 to 100 mg/m2. Toxicity was tolerable and reversible and included abdominal pain, transient elevation in serum creatinine, serum bilirubin, and serum transaminases. Less common side effects include fever, ascites or pleural effusion, and hiccups. Two of four patients with ocular melanoma had partial responses. Duration of response was 10 and 11 months. Among 8 patients with unresectable hepatoma, 2 patients had partial response for 10+ and 13 months, 2 had minor response for 2 months and 4+ months, 1 patient had stable disease for 5+ months, and 3 patients failed to respond. Of the six colon cancer patients treated, one had a partial response in the liver, but developed progressive nodal disease, and another patient had a partial response for 3 months. Chemoembolization of the liver with cisplatin and lipiodol is feasible and doses of cisplatin at least 100 mg/m2 are tolerable. Antitumor activity in metastatic ocular melanoma is encouraging but requires further study. |
| doi_str_mv | 10.1097/00000421-199410000-00010 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1097_00000421_199410000_00010</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>8092112</sourcerecordid><originalsourceid>FETCH-LOGICAL-c339t-9336a63cbb03c9a205a670c50561f1f12387835ec1681bc7132134a9be0009b33</originalsourceid><addsrcrecordid>eNo9kFtLxDAQhYMo67r6E4Q8-FrNZNqmeVwWb7Dgi4JvJU1TGmmbknSV9debvbgJIQznnGHmI4QCuwcmxQPbnZRDAlKmsCuS-ICdkTlkKJI0w89zMmdciAQF8ktyFcJXtGQ5EzMyK5jkAHxO2iUdWxUMfaVh2tRb6hqqW9M701eus79qsm6gP3ZqqbZh7GI9UDXUtLOjdbXraOM8Hb3tld_uhd5MKkzRp6Pn23iq1aCNvyYXjeqCuTn-C_Lx9Pi-eknWb8-vq-U60YhySiRirnLUVcVQS8VZpnLBdBYHhyZejoUoMDMa8gIqLQA5YKpkZeJyskJckOLQV3sXgjdNeRyuBFbu2JX_7MoTu3LPLkZvD9FxU_WmPgWPsKJ-d9RV0KprfFzMhpMt5TlKluIf3PR2ZQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A phase I study of chemoembolization with cisplatin and lipiodol for primary and metastatic liver cancer</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>FEUN, L. G ; REDDY, K. R ; LIVINGSTONE, A. S ; ARDALAN, B ; BENEDETTO, P ; YRIZARRY, J. M ; SAVARAJ, N ; GUERRA, J. J ; PURSER, R. K ; WALDMAN, S ; LEVI, J. U ; MOFFATT, F ; MORRELL, L</creator><creatorcontrib>FEUN, L. G ; REDDY, K. R ; LIVINGSTONE, A. S ; ARDALAN, B ; BENEDETTO, P ; YRIZARRY, J. M ; SAVARAJ, N ; GUERRA, J. J ; PURSER, R. K ; WALDMAN, S ; LEVI, J. U ; MOFFATT, F ; MORRELL, L</creatorcontrib><description>Twenty patients with either unresectable primary hepatocellular carcinoma or hepatic metastases were entered into a chemoembolization program with cisplatin and lipiodol; 19 patients were evaluable for response. Doses of cisplatin ranged from 40 to 100 mg/m2. Toxicity was tolerable and reversible and included abdominal pain, transient elevation in serum creatinine, serum bilirubin, and serum transaminases. Less common side effects include fever, ascites or pleural effusion, and hiccups. Two of four patients with ocular melanoma had partial responses. Duration of response was 10 and 11 months. Among 8 patients with unresectable hepatoma, 2 patients had partial response for 10+ and 13 months, 2 had minor response for 2 months and 4+ months, 1 patient had stable disease for 5+ months, and 3 patients failed to respond. Of the six colon cancer patients treated, one had a partial response in the liver, but developed progressive nodal disease, and another patient had a partial response for 3 months. Chemoembolization of the liver with cisplatin and lipiodol is feasible and doses of cisplatin at least 100 mg/m2 are tolerable. Antitumor activity in metastatic ocular melanoma is encouraging but requires further study.</description><identifier>ISSN: 0277-3732</identifier><identifier>EISSN: 1537-453X</identifier><identifier>DOI: 10.1097/00000421-199410000-00010</identifier><identifier>PMID: 8092112</identifier><identifier>CODEN: AJCODI</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Adult ; Aged ; Antineoplastic agents ; Biological and medical sciences ; Carcinoma, Hepatocellular - secondary ; Carcinoma, Hepatocellular - therapy ; Chemoembolization, Therapeutic - adverse effects ; Chemotherapy ; Cisplatin - adverse effects ; Cisplatin - therapeutic use ; Drug Administration Schedule ; Female ; Humans ; Iodized Oil - adverse effects ; Iodized Oil - therapeutic use ; Liver Neoplasms - pathology ; Liver Neoplasms - therapy ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Treatment Outcome</subject><ispartof>American journal of clinical oncology, 1994-10, Vol.17 (5), p.405-410</ispartof><rights>1994 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c339t-9336a63cbb03c9a205a670c50561f1f12387835ec1681bc7132134a9be0009b33</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4263904$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8092112$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>FEUN, L. G</creatorcontrib><creatorcontrib>REDDY, K. R</creatorcontrib><creatorcontrib>LIVINGSTONE, A. S</creatorcontrib><creatorcontrib>ARDALAN, B</creatorcontrib><creatorcontrib>BENEDETTO, P</creatorcontrib><creatorcontrib>YRIZARRY, J. M</creatorcontrib><creatorcontrib>SAVARAJ, N</creatorcontrib><creatorcontrib>GUERRA, J. J</creatorcontrib><creatorcontrib>PURSER, R. K</creatorcontrib><creatorcontrib>WALDMAN, S</creatorcontrib><creatorcontrib>LEVI, J. U</creatorcontrib><creatorcontrib>MOFFATT, F</creatorcontrib><creatorcontrib>MORRELL, L</creatorcontrib><title>A phase I study of chemoembolization with cisplatin and lipiodol for primary and metastatic liver cancer</title><title>American journal of clinical oncology</title><addtitle>Am J Clin Oncol</addtitle><description>Twenty patients with either unresectable primary hepatocellular carcinoma or hepatic metastases were entered into a chemoembolization program with cisplatin and lipiodol; 19 patients were evaluable for response. Doses of cisplatin ranged from 40 to 100 mg/m2. Toxicity was tolerable and reversible and included abdominal pain, transient elevation in serum creatinine, serum bilirubin, and serum transaminases. Less common side effects include fever, ascites or pleural effusion, and hiccups. Two of four patients with ocular melanoma had partial responses. Duration of response was 10 and 11 months. Among 8 patients with unresectable hepatoma, 2 patients had partial response for 10+ and 13 months, 2 had minor response for 2 months and 4+ months, 1 patient had stable disease for 5+ months, and 3 patients failed to respond. Of the six colon cancer patients treated, one had a partial response in the liver, but developed progressive nodal disease, and another patient had a partial response for 3 months. Chemoembolization of the liver with cisplatin and lipiodol is feasible and doses of cisplatin at least 100 mg/m2 are tolerable. Antitumor activity in metastatic ocular melanoma is encouraging but requires further study.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Hepatocellular - secondary</subject><subject>Carcinoma, Hepatocellular - therapy</subject><subject>Chemoembolization, Therapeutic - adverse effects</subject><subject>Chemotherapy</subject><subject>Cisplatin - adverse effects</subject><subject>Cisplatin - therapeutic use</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Humans</subject><subject>Iodized Oil - adverse effects</subject><subject>Iodized Oil - therapeutic use</subject><subject>Liver Neoplasms - pathology</subject><subject>Liver Neoplasms - therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Treatment Outcome</subject><issn>0277-3732</issn><issn>1537-453X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kFtLxDAQhYMo67r6E4Q8-FrNZNqmeVwWb7Dgi4JvJU1TGmmbknSV9debvbgJIQznnGHmI4QCuwcmxQPbnZRDAlKmsCuS-ICdkTlkKJI0w89zMmdciAQF8ktyFcJXtGQ5EzMyK5jkAHxO2iUdWxUMfaVh2tRb6hqqW9M701eus79qsm6gP3ZqqbZh7GI9UDXUtLOjdbXraOM8Hb3tld_uhd5MKkzRp6Pn23iq1aCNvyYXjeqCuTn-C_Lx9Pi-eknWb8-vq-U60YhySiRirnLUVcVQS8VZpnLBdBYHhyZejoUoMDMa8gIqLQA5YKpkZeJyskJckOLQV3sXgjdNeRyuBFbu2JX_7MoTu3LPLkZvD9FxU_WmPgWPsKJ-d9RV0KprfFzMhpMt5TlKluIf3PR2ZQ</recordid><startdate>19941001</startdate><enddate>19941001</enddate><creator>FEUN, L. G</creator><creator>REDDY, K. R</creator><creator>LIVINGSTONE, A. S</creator><creator>ARDALAN, B</creator><creator>BENEDETTO, P</creator><creator>YRIZARRY, J. M</creator><creator>SAVARAJ, N</creator><creator>GUERRA, J. J</creator><creator>PURSER, R. K</creator><creator>WALDMAN, S</creator><creator>LEVI, J. U</creator><creator>MOFFATT, F</creator><creator>MORRELL, L</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19941001</creationdate><title>A phase I study of chemoembolization with cisplatin and lipiodol for primary and metastatic liver cancer</title><author>FEUN, L. G ; REDDY, K. R ; LIVINGSTONE, A. S ; ARDALAN, B ; BENEDETTO, P ; YRIZARRY, J. M ; SAVARAJ, N ; GUERRA, J. J ; PURSER, R. K ; WALDMAN, S ; LEVI, J. U ; MOFFATT, F ; MORRELL, L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c339t-9336a63cbb03c9a205a670c50561f1f12387835ec1681bc7132134a9be0009b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Hepatocellular - secondary</topic><topic>Carcinoma, Hepatocellular - therapy</topic><topic>Chemoembolization, Therapeutic - adverse effects</topic><topic>Chemotherapy</topic><topic>Cisplatin - adverse effects</topic><topic>Cisplatin - therapeutic use</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Humans</topic><topic>Iodized Oil - adverse effects</topic><topic>Iodized Oil - therapeutic use</topic><topic>Liver Neoplasms - pathology</topic><topic>Liver Neoplasms - therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>FEUN, L. G</creatorcontrib><creatorcontrib>REDDY, K. R</creatorcontrib><creatorcontrib>LIVINGSTONE, A. S</creatorcontrib><creatorcontrib>ARDALAN, B</creatorcontrib><creatorcontrib>BENEDETTO, P</creatorcontrib><creatorcontrib>YRIZARRY, J. M</creatorcontrib><creatorcontrib>SAVARAJ, N</creatorcontrib><creatorcontrib>GUERRA, J. J</creatorcontrib><creatorcontrib>PURSER, R. K</creatorcontrib><creatorcontrib>WALDMAN, S</creatorcontrib><creatorcontrib>LEVI, J. U</creatorcontrib><creatorcontrib>MOFFATT, F</creatorcontrib><creatorcontrib>MORRELL, L</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>American journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>FEUN, L. G</au><au>REDDY, K. R</au><au>LIVINGSTONE, A. S</au><au>ARDALAN, B</au><au>BENEDETTO, P</au><au>YRIZARRY, J. M</au><au>SAVARAJ, N</au><au>GUERRA, J. J</au><au>PURSER, R. K</au><au>WALDMAN, S</au><au>LEVI, J. U</au><au>MOFFATT, F</au><au>MORRELL, L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A phase I study of chemoembolization with cisplatin and lipiodol for primary and metastatic liver cancer</atitle><jtitle>American journal of clinical oncology</jtitle><addtitle>Am J Clin Oncol</addtitle><date>1994-10-01</date><risdate>1994</risdate><volume>17</volume><issue>5</issue><spage>405</spage><epage>410</epage><pages>405-410</pages><issn>0277-3732</issn><eissn>1537-453X</eissn><coden>AJCODI</coden><abstract>Twenty patients with either unresectable primary hepatocellular carcinoma or hepatic metastases were entered into a chemoembolization program with cisplatin and lipiodol; 19 patients were evaluable for response. Doses of cisplatin ranged from 40 to 100 mg/m2. Toxicity was tolerable and reversible and included abdominal pain, transient elevation in serum creatinine, serum bilirubin, and serum transaminases. Less common side effects include fever, ascites or pleural effusion, and hiccups. Two of four patients with ocular melanoma had partial responses. Duration of response was 10 and 11 months. Among 8 patients with unresectable hepatoma, 2 patients had partial response for 10+ and 13 months, 2 had minor response for 2 months and 4+ months, 1 patient had stable disease for 5+ months, and 3 patients failed to respond. Of the six colon cancer patients treated, one had a partial response in the liver, but developed progressive nodal disease, and another patient had a partial response for 3 months. Chemoembolization of the liver with cisplatin and lipiodol is feasible and doses of cisplatin at least 100 mg/m2 are tolerable. Antitumor activity in metastatic ocular melanoma is encouraging but requires further study.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>8092112</pmid><doi>10.1097/00000421-199410000-00010</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0277-3732 |
| ispartof | American journal of clinical oncology, 1994-10, Vol.17 (5), p.405-410 |
| issn | 0277-3732 1537-453X |
| language | eng |
| recordid | cdi_crossref_primary_10_1097_00000421_199410000_00010 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adult Aged Antineoplastic agents Biological and medical sciences Carcinoma, Hepatocellular - secondary Carcinoma, Hepatocellular - therapy Chemoembolization, Therapeutic - adverse effects Chemotherapy Cisplatin - adverse effects Cisplatin - therapeutic use Drug Administration Schedule Female Humans Iodized Oil - adverse effects Iodized Oil - therapeutic use Liver Neoplasms - pathology Liver Neoplasms - therapy Male Medical sciences Middle Aged Pharmacology. Drug treatments Treatment Outcome |
| title | A phase I study of chemoembolization with cisplatin and lipiodol for primary and metastatic liver cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T23%3A36%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20phase%20I%20study%20of%20chemoembolization%20with%20cisplatin%20and%20lipiodol%20for%20primary%20and%20metastatic%20liver%20cancer&rft.jtitle=American%20journal%20of%20clinical%20oncology&rft.au=FEUN,%20L.%20G&rft.date=1994-10-01&rft.volume=17&rft.issue=5&rft.spage=405&rft.epage=410&rft.pages=405-410&rft.issn=0277-3732&rft.eissn=1537-453X&rft.coden=AJCODI&rft_id=info:doi/10.1097/00000421-199410000-00010&rft_dat=%3Cpubmed_cross%3E8092112%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/8092112&rfr_iscdi=true |